Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Mar 25;23(1):273.
doi: 10.1186/s12885-023-10761-1.

SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases

J A Crouzen  1 , A L Petoukhova  1 , M L D Broekman  1 , M Fiocco  2 , U J Fisscher  1 , J H Franssen  3 , C G M Gadellaa-van Hooijdonk  4 , M Kerkhof  1 , M Kiderlen  1 , M E Mast  1 , C M van Rij  5 , R Nandoe Tewarie  1 , M A E van de Sande  6 , P P G van der Toorn  7 , R Vlasman  8 , M J Vos  1 , N C M G van der Voort van Zyp  1 , R G J Wiggenraad  1 , L M Wiltink  9 , J D Zindler  10   11
Affiliations
Clinical Trial

SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases

J A Crouzen et al. BMC Cancer. .

Abstract

Background: Stereotactic radiosurgery (SRS) is a frequently chosen treatment for patients with brain metastases and the number of long-term survivors is increasing. Brain necrosis (e.g. radionecrosis) is the most important long-term side effect of the treatment. Retrospective studies show a lower risk of radionecrosis and local tumor recurrence after fractionated stereotactic radiosurgery (fSRS, e.g. five fractions) compared with stereotactic radiosurgery in one or three fractions. This is especially true for patients with large brain metastases. As such, the 2022 ASTRO guideline of radiotherapy for brain metastases recommends more research to fSRS to reduce the risk of radionecrosis. This multicenter prospective randomized study aims to determine whether the incidence of adverse local events (either local failure or radionecrosis) can be reduced using fSRS versus SRS in one or three fractions in patients with brain metastases.

Methods: Patients are eligible with one or more brain metastases from a solid primary tumor, age of 18 years or older, and a Karnofsky Performance Status ≥ 70. Exclusion criteria include patients with small cell lung cancer, germinoma or lymphoma, leptomeningeal metastases, a contraindication for MRI, prior inclusion in this study, prior surgery for brain metastases, prior radiotherapy for the same brain metastases (in-field re-irradiation). Participants will be randomized between SRS with a dose of 15-24 Gy in 1 or 3 fractions (standard arm) or fSRS 35 Gy in five fractions (experimental arm). The primary endpoint is the incidence of a local adverse event (local tumor failure or radionecrosis identified on MRI scans) at two years after treatment. Secondary endpoints are salvage treatment and the use of corticosteroids, bevacizumab, or antiepileptic drugs, survival, distant brain recurrences, toxicity, and quality of life.

Discussion: Currently, limiting the risk of adverse events such as radionecrosis is a major challenge in the treatment of brain metastases. fSRS potentially reduces this risk of radionecrosis and local tumor failure.

Trial registration: ClincalTrials.gov, trial registration number: NCT05346367 , trial registration date: 26 April 2022.

Keywords: Brain metastases; Brain necrosis; Fractionated stereotactic radiosurgery (fSRS); Hypofractionation; Local tumor failure; Radionecrosis; Stereotactic radiosurgery (SRS).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Example of treatment plan for multiple brain metastases
See this image and copyright information in PMC

References

    1. Lazaro T, Brastianos PK. Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncol. 2017;6(2):139–151. doi: 10.2217/cns-2016-0038. - DOI - PMC - PubMed
    1. Hartgerink D, Swinnen A, Roberge D, Nichol A, Zygmanski P, Yin FF, et al. LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. Acta Oncol. 2019;58(9):1275–1282. doi: 10.1080/0284186X.2019.1633016. - DOI - PubMed
    1. Niranjan A, Monaco E, Flickinger J, Dade LL. Guidelines for multiple brain metastases radiosurgery. Prog Neurol Surg. 2019 doi: 10.1159/000493055. - DOI - PubMed
    1. Hartgerink D, van der Heijden B, De Ruysscher D, Postma A, Ackermans L, Hoeben A, et al. Stereotactic radiosurgery in the management of patients with brain metastases of non-small cell lung cancer: Indications, decision tools and future directions. Front Oncol. 2018;8:154. doi: 10.3389/fonc.2018.00154. - DOI - PMC - PubMed
    1. Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Survival in Patients with Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020;38(32):3773–3784. doi: 10.1200/JCO.20.01255. - DOI - PMC - PubMed

Publication types

Associated data